Physician Survey to Reassess Effectiveness of Strattera Risk Minimisation Activities

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/8929
• EU PAS number:
  EUPAS4577
• Study ID:
  8929
• Official title and acronym:
  Physician Survey to Reassess Effectiveness of Strattera Risk Minimisation Activities
• DARWIN EU® study:
  No
• Study countries:
  Denmark

  Netherlands

  Sweden

  United Kingdom
• Study description:
  This is a survey to re-assess the effectiveness of the atomoxetine risk minimisation activities among physicians who prescribe Strattera and/or monitor patients being treated with Strattera.
• Study status:
  Finalised

Research institutions and networks

Institutions

GfK Health

Study timelines

Date when funding contract was signed

Actual: 26/04/2013

Study start date

Planned: 15/09/2013

Actual: 13/09/2013

Data analysis start date

Planned: 01/12/2013

Actual: 01/12/2013

Date of final study report

Planned: 28/03/2014

Actual: 27/03/2014

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company

Study protocol

Initial protocol

RMiP PASS protocol_p1

Updated protocol

RMiP PASS protocol_p1_mod

Regulatory

• Was the study required by a regulatory body?:
  No